Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen
Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen Uses, Dosage, Side Effects, Food Interaction and all others data.
Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
| Trade Name | Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen |
| Generic | Axalimogene filolisbac |
| Axalimogene filolisbac Other Names | Adxs hpv, Live, attenuated listeria monocytogenes bacteria, expressing human papilloma virus type 16-e7 tumor antigen, Raligize |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen
